Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

INTRODUCTION: The first cardiovascular safety trial in the sodium-glucose co-transporter-2 (SGLT2) inhibitor drug class, the Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, demonstrated significant cardiovascular risk reduction with empagliflozin. It...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Andrew, Feher, Michael, Munro, Neil, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380507/
https://www.ncbi.nlm.nih.gov/pubmed/28324484
http://dx.doi.org/10.1007/s13300-017-0254-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380507/
https://www.ncbi.nlm.nih.gov/pubmed/28324484
http://dx.doi.org/10.1007/s13300-017-0254-7

Ejemplares similares